Sabrina Aery, a 340B expert with more than 30 years of experience across hospitals, health plans, pharmaceutical manufacturers, and consulting, joins Perspectives to provide a 340B 101. She discusses the foundations of the program, how it works in practice, and how the program layers into the broader pharmaceutical pricing system. The episode concludes by discussing how the 340B program can impact the economics of a prescription drug and what biotech investors and executives can consider when evaluating potential 340B exposure.

Topics discussed include:

• Who qualifies as a 340B covered entity and which patients and drugs may fall within the program
• How 340B ceiling prices are determined
• How 340B can affect gross-to-net, net price, and revenue forecasting
• Three things biotech executives and investors can examine to assess a product’s potential 340B exposure

Whether you work in biotech or simply want to better understand the U.S. drug pricing system, this episode explains 340B and why it matters.

Show links:

Drug Channels: The 340B Program Hit $100 Billion in 2025: Has It Become Too Big to Reform?

Growth in the 340B Drug Pricing Program

Analysis of 340B modifier usage in Medicare Part B claims – ADVI

Date recorded: October 2, 2026